TRex Bio Leads 2 Drugmakers Pricing IPOs Totaling $162M
Two clinical-stage biotechnology firms, TRex Bio and Retension Pharmaceuticals, hit the public markets on Friday after raising a combined $162 million in their initial public offerings.
Taro Pharma Says MDL Deal Bars States' Duplicative Claims
Taro Pharmaceuticals USA asked a Connecticut federal judge to toss generic-drug price-fixing claims brought by a coalition of states on behalf of consumers that are duplicative of claims the consumers have alr... (more story)
Mayne, Ascend Cut $1M Generic Price-Fixing Deal With States
Ascend Laboratories, Mayne Pharma and Citron Pharma asked a Connecticut federal judge Thursday to sign off on a settlement with a coalition of states resolving claims the companies were involved in an illegal ... (more story)
Genesis Healthcare Gets OK For Amended $1B Asset Sale
A Texas bankruptcy judge Thursday approved the sale of Genesis Healthcare's 175 care facilities after being told that the debtor had reached an amended deal with the buyer that will add $15 million in cash to ... (more story)
Viatris To Buy Pacira BioSciences For $1.65B
Viatris has agreed to acquire non-opioid pain treatment maker Pacira BioSciences for $1.65 billion, with Cravath Swaine & Moore LLP advising Viatris and Ashurst Perkins Coie representing Pacira, the companies said Thursday.
3rd Circ. Upends Sandoz's $61.6M Award Against UTC
A Third Circuit panel on Wednesday erased Sandoz Inc.'s $61.6 million award in a breach of contract case against United Therapeutics Corp., in a decision that sidesteps the major pharmaceutical company's reque... (more story)